Skip to main content

Table 3 Presentation of all flares

From: Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study

 

Total (n = 520)

RA* (n = 333)

PsA (n = 100)

SpA (n = 87)

Peripheral arthritis, n (%)

442 (85.0)

333 (100)

67 (67.0)

42 (48.3)

Inflammatory back pain, n (%)

45 (8.7)

–

4 (4.0)

41 (47.1)

Buttock pain– sacroiliitis, n (%)

15 (2.9)

–

2 (2.0)

13 (14.9)

Enthesitis, n (%)

9 (1.7)

–

6 (6.0)

3 (3.4)

Dactylitis, n (%)

5 (1.0)

–

4 (4.0)

1 (1.1)

Skin rashes, n (%)

39 (7.5)

–

37 (37.0)

2 (2.3)

Uveitis, n (%)

9 (1.7)

–

1 (1.0)

8 (9.2)

Nail changes, n (%)

3 (0.6)

–

2 (2.0)

1 (1.1)

  1. *All patients with rheumatoid arthritis were considered to have a flare of peripheral arthritis
  2. PsA psoriatic arthritis, RA rheumatoid arthritis, SpA spondyloarthritis